Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-12054533-B2
Application number	US-202217858629-A
Country	US
Kind code	B2
Filing date	Jul 6, 2022
Priority date	Dec 6, 2019
Publication date	Aug 6, 2024
Grant date	Aug 6, 2024

Abstract

The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

First claim

What is claimed is:

1. A method of producing aflibercept from a host cell cultured in a chemically defined medium (CDM), comprising:
(a) culturing said host cell in said CDM under suitable conditions in which said host cell expresses aflibercept;
(b) purifying said aflibercept using anion exchange chromatography (AEX) and at least two of the following additional chromatography steps, in any order, selected from the group of Protein A, affinity chromatography, cation exchange chromatography (CEX), hydrophobic interaction chromatography (HIC), and mixed mode chromatography;
(c) collecting said aflibercept following purification wherein said aflibercept includes between 1% and 0.03% aflibercept with at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

2. The method of claim 1 , wherein said AEX uses a mobile phase flow through wash having a pH between 7.7 and 8.5 and conductivity between 1.9 mS/cm and 4.1 mS/cm.

3. The method of claim 1 , wherein said AEX uses a mobile phase flow through wash having a pH between 7.9 and 8.1 and conductivity between 2.4 mS/cm and 2.6 mS/cm.

4. The method of claim 1 , wherein said aflibercept comprises oxidized histidine amino acid residues, wherein the percent of oxidized histidine amino acid residues after purification is between 0.5% and 0.03%.

5. The method of claim 1 , wherein said aflibercept comprises oxidized tryptophan amino acid residues, wherein the percent of oxidized tryptophan amino acid residues after purification is between 0.5% and 0.2%.

6. The method of claim 1 , wherein the relative amount of oxidized His19 residue is reduced by 15% after purification in step (b).

7. The method of claim 1 , wherein the relative amount of oxidized His86 residue is reduced by 30% after step (b).

8. The method of claim 1 , wherein the relative amount of oxidized His95 residue is reduced by 25% after step (b).

9. The method of claim 1 , wherein the relative amount of oxidized His145 residue is reduced by 25% after step (b).

10. The method of claim 1 , wherein the relative amount of oxidized His209 residue is reduced by 30% after step (b).

11. The method of claim 1 , wherein the relative amount of oxidized Trp58 residue is reduced by 30% after step (b).

12. The method of claim 1 , wherein the relative amount of oxidized Trp138 residue is reduced by 10% after step (b).

13. The method of claim 1 , wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM, the cumulative concentration of iron in said CDM is less than or equal to 55.0 μM, the cumulative concentration of copper in said CDM is less than or equal to 0.8 μM, the cumulative concentration of zinc in said CDM is less than or equal to 56.0 μM, the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM, and the cumulative concentration of an antioxidant in said CDM is about 0.001 mM to about 10.0 mM for any single anti-oxidant and the cumulative concentration of all anti-oxidants is less than or equal to 30.0 mM.

14. The method of claim 1 , wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM and the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM.

15. The method of claim 1 , wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM and the cumulative concentration of an antioxidant in said CDM is about 0.001 mM to about 10.0 mM for any single anti-oxidant and the cumulative concentration of all anti-oxidants is less than or equal to 30.0 mM.

16. The method of claim 1 , wherein the cumulative concentration of nickel in said CDM is less than or equal to 0.4 μM and the cumulative concentration of iron in said CDM is less than or equal to 55.0 μM.

17. The method of claim 1 , wherein the cumulative concentration of copper in said CDM is less than or equal to 0.8 μM and the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM.

18. The method of claim 1 , wherein the cumulative concentration of iron in said CDM is less than or equal to 55.0 μM and the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM.

Assignees

• Regeneron Pharma

Inventors

• Tustian Andrew
• Vartak Ankit
• Daly Thomas
• Pyles Erica
• Palackal Nisha
• Wang Shunhai
• Li Ning

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title